Within the Transcatheter Aortic Valve Replacement Market , self-expanding valves hold a significant share, reflecting their widespread use and proven efficacy. Self-expanding valves are made of a metal frame (stent) that is compressed into a delivery catheter and then expands to its full size when released at the target site. These valves are designed to be highly flexible and conformable, adapting to the patient’s native anatomy. The Medtronic CoreValve/Evolut series is a leading example of a self-expanding valve.
While self-expanding valves lead, balloon-expandable valves are a key competitor. Balloon-expandable valves are mounted on a balloon catheter and are expanded by inflating the balloon at the target site. The Edwards Lifesciences Sapien series is the leading balloon-expandable valve. These valves are known for their precise placement and robust radial force. The competition between self-expanding and balloon-expandable valves has driven innovation and improved outcomes.
Other valve types include mechanically expandable valves and sutureless valves, which represent smaller segments.
The choice between self-expanding and balloon-expandable valves depends on factors such as patient anatomy, operator preference, and valve characteristics. Self-expanding valves are often preferred for patients with heavily calcified valves or challenging anatomy. Balloon-expandable valves are often preferred for their precise placement and lower rates of paravalvular leak.
The market is also segmented by transcatheter aortic valve (TAV) reference type, including direct access, transfemoral, and transapical. The transfemoral approach, where the valve is delivered through the femoral artery, is the most common and preferred approach due to its minimally invasive nature. Transapical and direct access approaches are used when transfemoral access is not feasible.
The growth of the self-expanding and balloon-expandable segments is driven by continuous innovation and clinical evidence supporting their safety and efficacy. The competition between the two major valve types has led to improved device design, smaller delivery systems, and better outcomes. As TAVR expands into lower-risk patients, the demand for both types of valves is expected to grow.
